Lactoferrin

Also known as: Bovine lactoferrin, bLF

A milk protein with newer anemia trials favoring ferrous sulfate and earlier positive pooled findings limited by heterogeneity.

A shallow ceramic dish of pale ivory powder on cream linen over dark green paper.
Editorial illustration

Lactoferrin is an iron-binding milk protein. Two large 2026 trials found bovine lactoferrin inferior to ferrous sulfate for the tested anemia outcomes in pregnant or nonpregnant women. Earlier pooled findings favored lactoferrin but had substantial heterogeneity. Its role needs assessment by formulation, population and whether iron was also given.5, 1, 2, 3

  • LEAP1 randomized 919 pregnant participants. The maternal composite of intravenous iron or late-pregnancy hemoglobin below 110 g/L favored ferrous sulfate.1
  • In 555 nonpregnant Bangladeshi women with iron-deficiency anemia, 200 or 400 mg/day lactoferrin was inferior to 60 mg/day elemental iron over 12 weeks.2
  • The 2024 meta-analysis searched through June 2022 and reported I² of 95.8% in its hemoglobin comparison.3

What is Lactoferrin?

Bovine lactoferrin can be purified from cow's milk or cheese whey. The EFSA food assessment concerns a specified purified ingredient and proposed exposures. Clinical studies use separately defined regimens, including comparisons with iron and combinations that retain iron treatment.5, 4

Where it comes from

Natural sources

  • Lactoferrin occurs in cow's milk.

How it's made

The assessed bovine food ingredient is isolated from whey or skimmed milk and purified.

What it does in products

  • Purified milk protein in specified foods
  • Ingredient studied in oral anemia regimens

Benefits

Anemia results depend on the regimen

limited evidence

The recent replacement trials change the interpretation of earlier pooled evidence.1, 2, 4

Ferrous sulfate performed better in both large 2026 comparisons. A separate open-label study in 185 people with chronic kidney disease found greater hemoglobin improvement when lactoferrin was added to liposomal iron. That finding concerns an add-on regimen in a specific clinical population.

Evidence scope and limitations

Bovine oral lactoferrin, selected anemia trials, an earlier meta-analysis and scoped food/allergen guidance.

  • The clinical papers and meta-analysis were checked through original indexed abstracts where full text was unavailable. Protocol details and adverse-event interpretation remain limited by that access.
  • The large 2026 trials address particular anemia populations. The CKD trial was open-label and retained iron in both arms.
  • The 2012 food-safety opinion addresses proposed exposures. This guide does not assess every recombinant protein, infant formula or infection-related claim.

Evidence last checked: 2026-11-14

Side effects & safety

Milk-protein allergic reaction (varies)Bovine lactoferrin is milk-derived. FDA identifies milk as a major allergen and advises avoidance of the responsible food in diagnosed allergy. Breathing difficulty or throat swelling requires emergency care.

Safety considerations

  • Pregnancy anemia requires clinical assessment. LEAP1's poorer maternal outcome with the tested lactoferrin regimen makes the choice of treatment consequential.
  • Review medicines and supplements with a clinician or pharmacist, as FDA advises. The selected trials provide a limited basis for evaluating broader drug combinations.
  • Not for: People with milk-protein allergy need to avoid the relevant milk-derived product and review its allergen declaration.
6, 5, 1, 7

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In anemia studies

LEAP1 used 200 mg/day bovine lactoferrin versus 80 mg/day ferrous sulfate. The Bangladesh trial tested 200 or 400 mg/day versus 60 mg/day elemental iron, with folic acid in every group. The CKD add-on study used 100 mg lactoferrin twice daily alongside 30 mg/day liposomal iron. These are research protocols requiring their original clinical context.

1, 2, 4

Regulatory status

  • U.S. dietary supplements follow FDA's supplement framework, including manufacturer responsibility for safety and labeling. A marketed supplement has no routine FDA premarket efficacy approval. EFSA's favorable 2012 opinion is limited to the proposed European food uses and exposure levels assessed.
5, 7

Why the older pooled result needs another look

The 2024 review's favorable average combined trials with markedly different results. Its June 2022 search cutoff predates the larger 2026 comparisons. Reading the pooled estimate alone would omit evidence directly relevant to choosing an anemia treatment.

The CKD study asks an additional question because both groups received iron. Keep the comparator visible when judging a claim that lactoferrin can replace iron. Different populations and co-treatments limit transfer between these findings.

3, 1, 2, 4

Frequently asked questions

Does a favorable food-safety opinion establish an anemia treatment?

EFSA assessed a purified bovine ingredient at specified food exposures. The anemia question is addressed by clinical comparisons, whose results differ with the regimen and patient group.5, 1, 4

The bottom line

For an anemia claim, check the patient group, the iron comparator and the newer trial results before interpreting lactoferrin's evidence.

References

  1. Said JM, O'Connell RL, Reynolds RM, et al.. Effects of oral bovine lactoferrin versus oral iron sulphate in iron-deficiency anaemia in pregnancy (LEAP1): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Obstetrics, Gynaecology, & Women's Health (2026) · randomized trial · DOI 10.1016/S3050-5038(26)00262-1; ACTRN12614000988651; November 2026, 2(11):e959–e972; indexed original abstract checked, full text unavailable
  2. Huda TM, Islam S, Ali NB, et al.. Bovine Lactoferrin Compared With Ferrous sulfate for Treating Iron-Deficiency Anemia in Bangladeshi Women—A Randomized Controlled Trial. The Journal of Nutrition (2026) · randomized trial · PMID 42302886; DOI 10.1016/j.tjnut.2026.101672; ACTRN12617001455358; August 2026 issue, online June 17; indexed original abstract checked, full text unavailable
  3. Christofi MD, Giannakou K, Mpouzika M, et al.. The effectiveness of oral bovine lactoferrin compared to iron supplementation in patients with a low hemoglobin profile: A systematic review and meta-analysis of randomized clinical trials. BMC Nutrition (2024) · meta analysis · PMID 38291525; DOI 10.1186/s40795-023-00818-6; January 30, 2024; indexed original abstract checked, search cutoff June 2022 and I² 95.8% retained in interpretation
  4. Divyaveer S, Kekan K, Kashyap M, et al.. Randomized Controlled Trial Comparing Lactoferrin+Iron with Iron Alone for Iron Deficiency Anemia in CKD. Clinical Journal of the American Society of Nephrology (2026) · randomized trial · PMID 42684832; DOI 10.2215/CJN.0000001204; CTRI/2020/04/024746; published online September 2, 2026; original abstract checked, full text unavailable
  5. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on bovine lactoferrin. EFSA Journal (2012) · safety assessment · DOI 10.2903/j.efsa.2012.2811; 10(7):2811; July 17, 2012; proposed food uses and exposure scope checked
  6. Food Allergies: What You Need to Know. U.S. Food and Drug Administration · government guidance · Current agency guidance checked November 14, 2026 for milk-derived protein labeling and serious-allergy response; access date is not publication date
  7. Questions and Answers on Dietary Supplements. U.S. Food and Drug Administration · government guidance · Undated current agency resource checked November 14, 2026 for premarket review and professional-consultation framework

Revision history

  1. Initial AI-assisted source compilation with claim-level citations, formulation distinctions and explicit evidence limitations; not independent medical review.